Analysis of In-Hospital Mortality of Patients with New Coronavirus Infection (COVID-19) of Clinical Centre of Sechenov University

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

INTRODUCTION: The epidemic of a new coronavirus infection (COVID-19) required a restructure of the entire healthcare system of the Russian Federation within a limited period of time. Here, the mortality of patients is the most important effective parameter that reflects successfulness of organization measures for improvement of the activity of medical institutions. The initial preparedness of the infrastructure permitted to rapidly deploy a hospital on the base of the Clinical Centre of Sechenov University for providing medical assistance to patients with COVID-19.

AIM: To analyze the in-hospital mortality of patients with COVID-19 at the Clinical Center of Sechenov University.

MATERIALS AND METHODS: The COVID-19 database (n = 19 230) of the Clinical Centre of Sechenov University for 2020–2022 was analyzed.

RESULTS: The overall in-hospital mortality in COVID-19 hospitals of the Clinical Centre of Sechenov University was 8.5%, which is the lower level compared to the data of foreign studies (Italy, Spain, Great Britain, USA, Iran). The main predictors of mortality are: basic — male gender, age (mainly > 75 years); existence of malignant neoplasms, diseases of the nervous system, diseases of the cardiovascular system, diseases of the endocrine system in patients; diseases occurring in the course of hospital treatment — artificial lung ventilation, past surgical interventions.

CONCLUSION: The working experience of the Clinical Center of Sechenov University shows a possibility for quick salvation of organizational tasks facing the healthcare system in the period of COVID-19 pandemic, with the results characterized by low lethality of hospitalized patients.

作者简介

Viktor Fomin

I. M. Sechenov First Moscow State Medical University (Sechenov University)

Email: fomin_v_v_1@staff.sechenov.ru
ORCID iD: 0000-0002-2682-4417
SPIN 代码: 8465-2747

MD, Dr. Sci. (Med.), Professor

俄罗斯联邦, Moscow

Valeriy Royuk

I. M. Sechenov First Moscow State Medical University (Sechenov University)

Email: vvroyuk@mail.ru
ORCID iD: 0000-0002-4966-3767
SPIN 代码: 7535-4008

MD, Cand. Sci. (Med.), Associate Professor

俄罗斯联邦, Moscow

Vladimir Reshetnikov

I. M. Sechenov First Moscow State Medical University (Sechenov University)

Email: resh1960@mail.ru
ORCID iD: 0000-0002-7853-7356
SPIN 代码: 4016-2059

MD, Dr. Sci. (Med.), Professor

俄罗斯联邦, Moscow

Ol’ga Volkova

I. M. Sechenov First Moscow State Medical University (Sechenov University)

Email: volkova_o_s@staff.sechenov.ru
ORCID iD: 0000-0002-4568-1298
SPIN 代码: 1758-1266

MD, Cand. Sci. (Med.)

俄罗斯联邦, Moscow

Natan Korshever

Saratov State Medical University named after V. I. Razumovsky

Email: korshever@bk.ru
ORCID iD: 0000-0002-5545-6844
SPIN 代码: 3665-2116

MD, Dr. Sci. (Med.), Professor

俄罗斯联邦, Saratov

Vasiliy Kozlov

Azerbaijan Medical University

编辑信件的主要联系方式.
Email: kvv.doc@gmfil.com
ORCID iD: 0000-0002-2389-3820
SPIN 代码: 7703-0013

MD, Cand. Sci. (Med.), Associate Professor

阿塞拜疆, Baku

参考

  1. Glybochko PV, Svistunov AA, Fomin VV, et al. Rol’ klinik Sechenovskogo Universiteta v okazanii pomoshchi patsiyentam s novoy koronavirusnoy infektsiyey (COVID-19). National Health Care (Russia). 2020;1(1):23–7. (In Russ).
  2. Glybochko PV, Fomin VV, Moiseev SV, et al. Risk factors for the early develop- ment of septic shock in patients with severe COVID-19. Therapeutic Archive. 2020;92(11):17–23. (In Russ). doi: 10.26442/00403660.2020.11.000780
  3. Nikitin IG, Melekhov AV, Sayfullin MA, et al. Organizing the medical care for the COVID-19 patients in non-infectiousMoscow hospital: reassignment experience. Therapeutic Archive. 2020;92(11):31–7. (In Russ). doi: 10.26442/00403660.2020.11.000838
  4. Order of the Ministry of Health of the Russian Federation dated on 19 March, 2020 No. 198n «O vremennom poryadke organizatsii raboty meditsinskikh organizatsiy v tselyakh realizatsii mer po profilaktike i snizheniyu riskov rasprostraneniya novoy koronavirusnoy infektsii COVID-19». Available at: https://docs.cntd.ru/document/564482310. Accessed: 2023 August 31. (In Russ).
  5. Guskova ON, Dominikan IE, Volodko SN. Mortality, hospital mortality statistics and tanatological analysis of lethal outcomes in patients with new coronavirus infection (COVID-19) in Tver region. Verkhnevolzhskiy Meditsinskiy Zhurnal. 2021;20(4):8–13. (In Russ).
  6. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62. doi: 10.1016/S0140-6736(20)30566-3
  7. Kuzovlev АN, Ermokhina LV, Melnikova NS, et al. A nomogram for predicting hospital mortality in patients with COVID-19 admitted to the intensive care unit. Messenger of Anesthesiology and Resuscitation. 2022;19(1):6–17. (In Russ). doi: 10.21292/2078-5658-2022-19-1-6-17
  8. Mokrysheva NG, Shestakova MV, Vikulova OK, et al. Analysis of risk factors for COVID-19-related fatal outcome in 337991 patients with type 1 and type 2 diabetes mellitus in 2020–2022 years: Russian nationwide retrospective study. Diabetes Mellitus. 2022; 25(5): 404–17. (In Russ). doi: 10.14341/DM12954
  9. Mityakov SN. Justification of factors influencing at the level of mortality from COVID-19. Razvitiye i Bezopasnost’. 2021;(4):4–18. (In Russ). doi: 10.46960/2713-2633_2021_4_4
  10. Sagatkali AS, Tusupkaliyeva KSh, Urazayeva ST, et al. Analysis of morbidity and risk factors for mortality from COVID-19 (literature review). West Kazakhstan Medical Journal. 2022;64(1):9–17. (In Russ). doi: 10.24412/2707-6180-2022-64-9-17
  11. Ssentongo P, Rastad H, Karim H, et al. Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: A systematic review and meta-analysis. PLoS One. 2020;15(8):e0238215. doi: 10.1186/s13098-020-00565-9
  12. Lai X, Wang M, Qin C, et al. Coronavirus Disease 2019 (COVID-2019) Infection Among Health Care Workers and Implications for Prevention Measures in a Tertiary Hospital in Wuhan, China. JAMA Netw Open. 2020;3(5):e209666. doi: 10.1001/jamanetworkopen.2020.9666
  13. Lee LY, Cazier J–B, Angelis V, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020;395(10241):1919-26. doi: 10.1016/S0140-6736(20)31173-9
  14. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239–42. doi: 10.1001/jama.2020.2648

补充文件

附件文件
动作
1. JATS XML

版权所有 © Eco-Vector, 2023


 


Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).